Vevoctadekin
- Generic Name
- Vevoctadekin
ST-067 and Teclistamab for the Treatment of Relapsed or Refractory Multiple Myeloma
Phase 1
Recruiting
- Conditions
- Recurrent Multiple MyelomaRefractory Multiple Myeloma
- Interventions
- Procedure: Bone Marrow AspirationProcedure: Bone Marrow BiopsyOther: Medical Chart ReviewProcedure: Biospecimen Collection
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2025-01-28
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 20
- Registration Number
- NCT06588660
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
DR-18 for the Treatment of Relapsed or Persistent Acute Myeloid Leukemia or Myelodysplastic Syndrome After Hematopoietic Cell Transplantation, the DR. DREAM Trial
Phase 1
Recruiting
- Conditions
- Recurrent Myelodysplastic SyndromeAcute Myeloid LeukemiaMyelodysplastic SyndromeRecurrent Acute Myeloid Leukemia
- Interventions
- Procedure: Biospecimen CollectionProcedure: Bone Marrow Aspiration
- First Posted Date
- 2024-07-09
- Last Posted Date
- 2025-01-28
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 20
- Registration Number
- NCT06492707
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
Phase 1
Recruiting
- Conditions
- CancerSquamous Cell Carcinoma of the Head and NeckNon Small Cell Lung CancerRenal Cell CarcinomaMSI-HighSolid TumorCarcinomaMelanomaTriple-negative Breast Cancer
- Interventions
- First Posted Date
- 2021-03-08
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Simcha IL-18, Inc.
- Target Recruit Count
- 316
- Registration Number
- NCT04787042
- Locations
- 🇺🇸
HonorHealth Research Institute, Scottsdale, Arizona, United States
🇺🇸Yale Cancer Center, New Haven, Connecticut, United States
🇺🇸Moffitt Cancer Center, Tampa, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath